Navigation Links
knowledge of proliferative sickle cell retinopathy can help Prevent eye trauma

Sickle cell disease is an inherited blood disorder that affects the hemoglobin protein found in red blood cells. Visual loss has been reported in 10- 20% of eyes in patients with this disease, a high figure that // may reflect ascertainment bias towards detecting patients with symptoms. Proliferative sickle cell retinopathy (PSR) is the principal contributor to visual loss, but the patients remain asymptomatic unless traumatic complications such as vitreous hemorrhage or retinal detachment (RD) occur.

A recent study, to be published in the November issue of Ophthalmology, details a longitudinal study done over 20 years to describe the incidence, prevalence, and natural history of proliferative sickle cell retinopathy (PSR) in a patient population free from the bias of symptomatic referral, followed from birth.

This work, supported by the Wellcome Trust, London, United Kingdom, confirms a greater incidence and severity of PSR in sickle cell disease, and shows that spontaneous regression occurred in 32% of PSR-affected eyes. Permanent visual loss was uncommon in subjects observed up to the age of 26 years. The discrepancy between the frequency of PSR, which concerns the ophthalmologist, and that of visual loss, which concerns the patient, raises a note of caution. It calls into question the justification of routine screening and prophylactic treatment, particularly if it is directed towards prevention of permanent visual loss rather than transient loss from hemorrhage.

Knowledge of the natural history of PSR is essential because the prevention of this visual loss and eye trauma is dependent on the early detection and treatment of proliferative sickle cell retinopathy.
'"/>




Page: 1

Related medicine news :

1. Spreading knowledge to doctors about herbal medicine
2. Guidant sold defective defibrillators with full knowledge
3. India set to become the global knowledge hub
4. New law to protect traditional knowledge
5. Zinc may enhance growth in Young sickle cell patients
6. Gene to identify risk of stroke in sickle cell anemia
7. New treatment for babies with sickle cell anemia
8. Diabetic retinopathy in pre-diabetes conditions
9. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
10. Prevention is better than cure
11. Prevention of cataracts
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a provider ... and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and ... biometric face recognition to enable users to check in and out from anywhere ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process ... in power plant water and steam. , Chlorides and sulfates cause pitting and ... to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels ...
(Date:3/28/2017)... Florida (PRWEB) , ... March 28, 2017 , ... The ... Corp to raise money to for the Toys for Tots Literacy Campaign at their ... budget in excess of $70 billion, the U.S. ranks at number 14 internationally in ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... VICTORIA and TORONTO , ... Canada,s leading full service medical device development ... Group, the visionary Toronto -based medical ... entity will better serve medtech companies throughout ... increased resources and experienced medical device talent spanning the ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, ... in Israel . This new business entity, Emosis ... mostly dedicated to research and development of novel assays complementing the ... also, when relevant, locally support commercialization and sales development of Emosis ... This strategic ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: